Premium
Successful peripheral blood stem‐cell autograft with a near‐critical dose of myeloid progenitor cells in acute non‐lymphoblastic leukaemia in relapse
Author(s) -
Juttner Christopher A.,
To L. Bik,
Ho James Q.K.,
Thorp Dawn L.,
Kimber Richard J.
Publication year - 1987
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1987.tb133460.x
Subject(s) - medicine , progenitor cell , bone marrow , stem cell , myeloid , aplasia , hematology , platelet , surgery , gastroenterology , immunology , biology , genetics
Rapid, complete and sustained haemopoietic reconstitution was achieved in a 69‐year‐old man with acute non‐lymphoblastic leukaemia in relapse who received an autograft of peripheral blood cells that were collected during very early remission. The patient received 1.7 × 10 8 nucleated cells/kg bodyweight containing 63 × 10 4 myeloid progenitor cells (CFU‐GM)/kg bodyweight. Trilineage engraftment was evident in the bone marrow seven days after the graft. Normal neutrophil and platelet counts were attained by day 17, on which day the patient was discharged from hospital. He remained in complete remission three months after the graft with normal blood counts and bone‐marrow cellularity. The rapid and sustained haemopoietic activity in this patient, in conjunction with our previous experience of four other patients who received autografts with peripheral blood stem cells, supports the concept we have proposed that a minimum CFU‐CM dose of 50 × 10 4 /kg bodyweight produces complete and sustained engraftment. The rapid recovery minimizes aplasia‐related risks and suggests that such autografting can be carried out safely in first remission even in older patients. This technique should be considered as a new therapeutic option for patients with acute non‐lymphoblastic leukaemia.